• Publications
  • Influence
Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
BACKGROUND AIMS Protocols for the production of CD19-specific chimeric antigen receptor (CAR19) T cells are often complex and expensive because of the use of retroviral and lentiviral vectors or theExpand
  • 42
  • 2
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors.
We compared outcomes for 2 retrospective cohorts of patients undergoing reduced-intensity conditioning (RIC) therapy transplants using haploidentical related donors and post-transplant prophylaxisExpand
  • 28
  • 1
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an
High-dose cyclophosphamide given early after allogeneic hemopoietic cell transplantation has been shown to be effective prophylaxis against graft-versus-host disease (GVHD) in the setting ofExpand
  • 28
  • 1
Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients.
BACKGROUND AIMS Varicella zoster virus (VZV) causes life-long latent infection in healthy individuals, which reactivates in 10-68% of stem cell transplant patients. Reconstituting immunity throughExpand
  • 20
  • 1
Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study
Population-based evidence on second cancer risk following autologous haematopoietic SCT (HCT) is lacking. We quantified second cancer risk for a national, population-based cohort of adult AustraliansExpand
  • 21
Haploidentical bone marrow transplants for haematological malignancies using non‐myeloablative conditioning therapy and post‐transplant immunosuppression with cyclophosphamide: results from a single
To demonstrate safety and efficacy of haploidentical bone marrow transplantation with non‐myeloablative conditioning and high‐dose post‐transplant cyclophosphamide in adult patients with leukaemia orExpand
  • 11
Anncaliia algerae Microsporidial Myositis, New South Wales, Australia
We describe the successful management of Anncaliia algerae microsporidial myositis in a man with graft versus host disease after hemopoietic stem cell transplantation. We also summarize clinicalExpand
  • 6
  • PDF
Low dose PD‐1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD
Dunleavy, K., Pittaluga, S., Maeda, L.S., Advani, R., Chen, C.C., Hessler, J., Steinberg, S.M., Grant, C., Wright, G., Varma, G., Staudt, L.M., Jaffe, E.S. & Wilson, W.H. (2013) Dose-adjustedExpand
  • 3
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
We sought to determine factors associated with the overall survival from relapse (OSR) of acute myeloid leukaemia (AML) after allogeneic haemopoietic stem cell transplantation (alloHSCT) and theExpand
  • 5
Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single‐centre case series
Graft failure affects approximately 5% of allogeneic stem cell transplants, with a poor prognosis. Salvage second allogeneic stem cell transplantation (alloSCT2) is limited by high rates ofExpand
  • 1